February 2020

Endotronix

Endotronix Announces Enrollment of the First Patients in the PROACTIVE-HF Pivotal Trial

Endotronix, Latest News / By

Lisle, Illinois.  February 18, 2020.  Seroba’s portfolio company, Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), today announced the enrollment of the first two patients in the PROACTIVE-HF pivotal trial. The trial is a pre-market investigational device exempt (IDE) study evaluating the safety and efficacy …

Endotronix Announces Enrollment of the First Patients in the PROACTIVE-HF Pivotal Trial Read More »

Cancer Killers

Fusion Announces the Appointment of Pablo J. Cagnoni, M.D. to its Board of Directors

Fusion, Latest News / By

Boston, Massachusetts & Hamilton, Ontario.  February 6, 2020.   Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted alpha therapeutics, has announced the appointment of Pablo J. Cagnoni, M.D., to the board of directors. Dr. Cagnoni’s appointment as an independent director adds an oncology drug development leader as the Company advances …

Fusion Announces the Appointment of Pablo J. Cagnoni, M.D. to its Board of Directors Read More »

Innovo

Atlantic Therapeutics Announces FDA Clearance for Over-the-Counter Use of INNOVO®

Atlantic, Latest News / By

GALWAY, Ireland.  6 February 2020.  Seroba’s portfolio  company, Atlantic Therapeutics, a global medical device manufacturer, today announced that the U.S. Food and Drug Administration (FDA) has granted over-the-counter (OTC) clearance to INNOVO®, a non-invasive, clinically proven and wearable device for the treatment of stress urinary incontinence (SUI) in adult females. This approval represents a major …

Atlantic Therapeutics Announces FDA Clearance for Over-the-Counter Use of INNOVO® Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top